Publications

Show details

Interpharma members are constantly working to develop new research methods and to minimise the number of laboratory animals. However, animal experiments remain essential for researching ubiquitous diseases such as cancer, multiple sclerosis and Alzheimer’s disease, and in developing new treatments. It is therefore important that pharmaceutical companies give top priority to responsible animal use and actively implement the 10-point Animal Welfare Charter adopted by member companies of Interpharma in 2010.

Show details

The most important facts and figures on Switzerland’s healthcare and pharma landscape

Show details

Vision for Switzerland as a pharma hub in 2030: «Switzerland is still Europe's leading pharma hub in 2030. It benefits from high-quality medical innovation and is able to fund this innovation in the long run and sustainably. The pharmaceutical industry is a key contributor to the prosperity and quality of life of people in Switzerland.»

Show details

Show details

The annual report provides information on Interpharma's priorities and activities as well as key figures and information about the research-based pharmaceutical industry. The texts are accompanied by illustrations and graphics. The report contains the major regional and national key figures for the pharmaceutical industry, including gross value added, headcount, productivity, exports and R&D expenditures. It also describes the major communication projects and political topics.